Melissa A Rosenkranz1, Douglas C Dean2, Barbara B Bendlin3, Nizar N Jarjour4, Stephane Esnault4, Henrik Zetterberg5, Amanda Heslegrave6, Michael D Evans7, Richard J Davidson8, William W Busse4. 1. Department of Psychiatry, University of Wisconsin-Madison, Madison, Wisc; Center for Healthy Minds, University of Wisconsin-Madison, Madison, Wisc. Electronic address: melissa.rosenkranz@wisc.edu. 2. Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisc; Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisc; Waisman Center, University of Wisconsin-Madison, Madison, Wisc. 3. Department of Medicine, University of Wisconsin-Madison, Madison, Wisc; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, Madison, Wisc. 4. Department of Medicine, University of Wisconsin-Madison, Madison, Wisc. 5. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom. 6. UK Dementia Research Institute at UCL, London, United Kingdom. 7. Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minn. 8. Department of Psychiatry, University of Wisconsin-Madison, Madison, Wisc; Center for Healthy Minds, University of Wisconsin-Madison, Madison, Wisc; Department of Psychology, University of Wisconsin-Madison, Madison, Wisc.
Abstract
BACKGROUND: Epidemiologic studies have shown that Alzheimer's disease (AD) and related dementias (ADRD) are seen more frequently with asthma, especially with greater asthma severity or exacerbation frequency. OBJECTIVE: To examine the changes in brain structure that may underlie this phenomenon, we examined diffusion-weighted magnetic resonance imaging (dMRI) and blood-based biomarkers of AD (phosphorylated tau 181, p-Tau181), neurodegeneration (neurofilament light chain, NfL), and glial activation (glial fibrillary acidic protein, GFAP). METHODS: dMRI data were obtained in 111 individuals with asthma, ranging in disease severity from mild to severe, and 135 healthy controls. Regression analyses were used to test the relationships between asthma severity and neuroimaging measures, as well as AD pathology, neurodegeneration, and glial activation, indexed by plasma p-Tau181, NfL, and GFAP, respectively. Additional relationships were tested with cognitive function. RESULTS: Asthma participants had widespread and large-magnitude differences in several dMRI metrics, which were indicative of neuroinflammation and neurodegeneration, and which were robustly associated with GFAP and, to a lesser extent, NfL. The AD biomarker p-Tau181 was only minimally associated with neuroimaging outcomes. Further, asthma severity was associated with deleterious changes in neuroimaging outcomes, which in turn were associated with slower processing speed, a test of cognitive performance. CONCLUSIONS: Asthma, particularly when severe, is associated with characteristics of neuroinflammation and neurodegeneration, and may be a potential risk factor for neural injury and cognitive dysfunction. There is a need to determine how asthma may affect brain health and whether treatment directed toward characteristics of asthma associated with these risks can mitigate these effects.
BACKGROUND: Epidemiologic studies have shown that Alzheimer's disease (AD) and related dementias (ADRD) are seen more frequently with asthma, especially with greater asthma severity or exacerbation frequency. OBJECTIVE: To examine the changes in brain structure that may underlie this phenomenon, we examined diffusion-weighted magnetic resonance imaging (dMRI) and blood-based biomarkers of AD (phosphorylated tau 181, p-Tau181), neurodegeneration (neurofilament light chain, NfL), and glial activation (glial fibrillary acidic protein, GFAP). METHODS: dMRI data were obtained in 111 individuals with asthma, ranging in disease severity from mild to severe, and 135 healthy controls. Regression analyses were used to test the relationships between asthma severity and neuroimaging measures, as well as AD pathology, neurodegeneration, and glial activation, indexed by plasma p-Tau181, NfL, and GFAP, respectively. Additional relationships were tested with cognitive function. RESULTS: Asthma participants had widespread and large-magnitude differences in several dMRI metrics, which were indicative of neuroinflammation and neurodegeneration, and which were robustly associated with GFAP and, to a lesser extent, NfL. The AD biomarker p-Tau181 was only minimally associated with neuroimaging outcomes. Further, asthma severity was associated with deleterious changes in neuroimaging outcomes, which in turn were associated with slower processing speed, a test of cognitive performance. CONCLUSIONS: Asthma, particularly when severe, is associated with characteristics of neuroinflammation and neurodegeneration, and may be a potential risk factor for neural injury and cognitive dysfunction. There is a need to determine how asthma may affect brain health and whether treatment directed toward characteristics of asthma associated with these risks can mitigate these effects.
Authors: Michael C Peters; Kelly Wong McGrath; Gregory A Hawkins; Annette T Hastie; Bruce D Levy; Elliot Israel; Brenda R Phillips; David T Mauger; Suzy A Comhair; Serpil C Erzurum; Mats W Johansson; Nizar N Jarjour; Andrea M Coverstone; Mario Castro; Fernando Holguin; Sally E Wenzel; Prescott G Woodruff; Eugene R Bleecker; John V Fahy Journal: Lancet Respir Med Date: 2016-06-06 Impact factor: 30.700
Authors: E Sherwood Brown; Dixie J Woolston; Alan Frol; Leonardo Bobadilla; David A Khan; Margaret Hanczyc; A John Rush; James Fleckenstein; Evelyn Babcock; C Munro Cullum Journal: Biol Psychiatry Date: 2004-03-01 Impact factor: 13.382
Authors: Oliver Preische; Stephanie A Schultz; Anja Apel; Jens Kuhle; Stephan A Kaeser; Christian Barro; Susanne Gräber; Elke Kuder-Buletta; Christian LaFougere; Christoph Laske; Jonathan Vöglein; Johannes Levin; Colin L Masters; Ralph Martins; Peter R Schofield; Martin N Rossor; Neill R Graff-Radford; Stephen Salloway; Bernardino Ghetti; John M Ringman; James M Noble; Jasmeer Chhatwal; Alison M Goate; Tammie L S Benzinger; John C Morris; Randall J Bateman; Guoqiao Wang; Anne M Fagan; Eric M McDade; Brian A Gordon; Mathias Jucker Journal: Nat Med Date: 2019-01-21 Impact factor: 53.440
Authors: Ajay Kumar Nair; Carol A Van Hulle; Barbara B Bendlin; Henrik Zetterberg; Kaj Blennow; Norbert Wild; Gwendlyn Kollmorgen; Ivonne Suridjan; William W Busse; Melissa A Rosenkranz Journal: Alzheimers Dement (N Y) Date: 2022-07-08
Authors: Rebecca Rosen; Yongzhao Shao; Qiao Zhang; Jia Bao; Yian Zhang; Arjun Masurkar; Thomas Wisniewski; Nina Urban; Joan Reibman Journal: Int J Environ Res Public Health Date: 2022-03-15 Impact factor: 3.390